Orally-administered  silver sulfadiazine: chemotherapy and toxicology in CF-1 mice; Plasmodium berghei (Malaria) and Pseudomonas aeruginosa.
Silver sulfadiazine when administered orally and subcutaneously to CF-1 mice in doses not exceeding 1,050 mg/kg proved to have minimal toxicity. No pathology or abnormal reactions were seen in CF-1 mice after receiving 1,050 mg/kg orally and subcutaneously once a day for 30 days. Silver sulfadiazine in doses of 1,050 mg/kg, once a day for 5 days cured mice of Plasmodium berghei even after splenectomy. Parasitemia was reduced to zero in 1-3 days and antimalarial activity was not inhibited significantly with doses of 313 mg/kg/day of PABA, thereby indicating that silver sulfadiazine's antimalarial mode of action is different from that of the sulfonamides. Doses of 1,050 mg/kg/day had significant activity against systemic infections of Pseudomonas aeruginosa.
D000284:Administration, Oral; D000818:Animals; D007279:Injections, Subcutaneous; D008288:Malaria / Q000188:drug therapy*; D051379:Mice; D008815:Mice, Inbred Strains; D010962:Plasmodium berghei; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa; D012834:Silver / Q000008:administration & dosage / Q000627:therapeutic use; D013411:Sulfadiazine / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use* / Q000633:toxicity
D013411:Sulfadiazine; D012834:Silver